Delonix Bioworks Doses First Participant in DX-104 Trial
SHANGHAI, China, July 13, 2026 Delonix Bioworks, a clinical-stage biotechnology company specializing in genetically engineered bacterial vaccines, has announced...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
SHANGHAI, China, July 13, 2026 Delonix Bioworks, a clinical-stage biotechnology company specializing in genetically engineered bacterial vaccines, has announced...
